Leisa Zigman Joins The Genome Partnership Board
The Genome Partnership, the organization that hosts the renowned Advances in Genome Biology and Technology (AGBT) meetings, announced today at its 25th anniversary AGBT General Meeting that former AGBT president Leisa Zigman has joined its board of directors.
Zigman, a respected journalist and former AGBT president, brings a wealth of leadership experience and a deep commitment to advancing genomics research and collaboration. Her tenure as president saw significant growth in AGBT's impact, fostering scientific innovation and strengthening the organization's position as a premier convenor of the genomics community.
'Leisa's contributions to AGBT have been instrumental in shaping the success of our meetings and mission,' said Wendy Vlieks, president of The Genome Partnership. 'Announcing her appointment at our 25th anniversary General Meeting is especially fitting, as she has played a key role in AGBT's evolution. We are thrilled to have her join The Genome Partnership board, where her insights and expertise will continue to drive our commitment to advancing discovery and innovation in genomics.'
Zigman's leadership has been pivotal in expanding AGBT's reach across key areas of genomic science, including precision health, agriculture and foundational research. As a board member, she will support strategic initiatives that enhance The Genome Partnership's role in fostering meaningful scientific exchange and collaboration.
'Leisa has been a driving force behind AGBT's growth and influence,' said Richard Wilson, chair of The Genome Partnership board and executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital. 'Her leadership and vision have helped shape the genomics community, and I have no doubt that she will continue to be an invaluable asset to The Genome Partnership in this new role.'
'I am honored to join The Genome Partnership board and look forward to supporting its mission in this new capacity,' Zigman said. 'The organization has long been a catalyst for transformative genomics research, and I am excited to contribute to its continued success.'
For more than 25 years, The Genome Partnership has provided a forum for researchers, industry leaders and policymakers to discuss the most groundbreaking advances in genomics. With Zigman's appointment, the organization reinforces its dedication to leadership and excellence in the field.
About The Genome Partnership
The Genome Partnership is a not-for-profit organization committed to advancing research, promoting education and fostering dialogue in genomics and life sciences. Through its globally recognized AGBT meetings, the organization convenes leading experts to discuss cutting-edge scientific advancements and applications.
SOURCE: The Genome Partnership
Copyright Business Wire 2025.
PUB: 02/24/2025 08:10 AM/DISC: 02/24/2025 08:10 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
Business Wire
3 hours ago
- Business Wire
Workplace Injuries Are Reduced with Employee Appreciation
LOUGHTON, England--(BUSINESS WIRE)--Latest research reveals that frequently recognising employees for their efforts and achievements can decrease the likelihood of workplace injuries among French workers by up to 50%. This is a key finding from O.C. Tanner's 2025 Global Culture Report which gathered data and insights from 38,075 workers from 27 countries including 1,208 from France. The report highlights how feeling unappreciated worsens mental health and this then increases the likelihood of workplace accidents. Robert Ordever, European MD of O.C. Tanner explains: 'There's a clear link between deteriorating mental health and greater instances of workplace injuries, with mental illness often leading to decreased concentration, reduced cognitive function, and impaired decision-making abilities. Workers struggling with their mental health have their condition worsened when they feel unappreciated by their managers and colleagues.' The Report highlights how regularly recognising employees for their efforts and achievements, not only improves workers' wellbeing, but noticeably reduces the odds of them reporting a workplace accident. Employees suffering from burnout are 50% less likely to have a workplace accident when their organisation has a formal recognition programme in place. For those workers with probable depression, their odds of reporting a workplace accident are 11% when their organisation is WITHOUT a recognition programme. For workers with probable depression but WITH a recognition programme in place, their odds of reporting a workplace accident are reduced to just 8%. Ordever says, 'Implementing a recognition programme that allows all employees to regularly express gratitude to colleagues, not only reduces the likelihood of burnout, anxiety, and depression, but also cuts the number of workplace injuries. But it's important to note that having a recognition programme is not enough in itself. The organisation must champion the giving of appreciation on a daily basis, and encourage recognition that's sincere, tailored to the individual and meaningful. When the importance of recognition is understood and prioiritised, organisations can enjoy truly impactful business outcomes.' About 2025 Global Culture Report The O.C. Tanner Institute uses multiple research methods to support the Global Culture Report, including interviews, focus groups, cross-sectional surveys, and a longitudinal survey. Qualitative findings came from 27 focus groups among employees, leaders, and HR practitioners of larger organisations. About O.C. Tanner O.C. Tanner is the global leader in personalised employee recognition solutions that improve workplace cultures so people feel appreciated, do their best work, and stay. Its Culture Cloud is a suite of apps and solutions, including recognition, service awards, wellbeing, leadership, and celebrations that help people thrive at work. O.C. Tanner provides these and other services for thousands of the most respected companies in the world. For more information visit
Yahoo
8 hours ago
- Yahoo
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif., June 09, 2025--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. "The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever," said Olivier Lauzeral, General Manager of Somnics Health. "With iNAP Essentials, we're removing the affordability hurdle." A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. "Adherence is one of iNAP's biggest strengths," added Lauzeral. "When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA." What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. "We built this program with transparency and simplicity at its core," said Lauzeral. "It's everything you need to start treatment—nothing you don't." Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. "Some patients want to purchase the device outright. With Affirm, they can do that without financial strain," said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. "Physicians are seeing the value of iNAP in improving adherence and patient satisfaction," Lauzeral emphasized. "When patients feel empowered, they stay engaged—and that's the future of sleep medicine." Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. "This isn't just about access—it's about fairness," said Lauzeral. "Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health." About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence. Learn More: View source version on Contacts Press Contact: Olivier Lauzeral – olivier@ Follow us on: LinkedIn | Facebook | YouTube Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
